Evidence map›Paper›PMID 32131885›Full record

ArticleTrials2020

A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial.

Brian Eichner, Le Ann C Michaels, Kelsey Branca, Katrina Ramsey, Julie Mitchell, Cynthia D Morris, Lyle J Fagnan, Rowena J Dolor, Nancy Elder, David L Hahn and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03409367 (A Community-based Assessment of Skin Care, Allergies, and Eczema), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03409367 nacompletednot on this map

A Community-based Assessment of Skin Care, Allergies, and Eczema

TypeinterventionalSponsorOregon Health and Science UniversityRan2018 to 2024Enrolled1,260ConditionsAtopic Dermatitis, Atopic Disorders, Eczema, Atopic EczemaArmsParticipant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Brian EichnerDuke Primary Care Research Consortium, Duke University, Durham, NC, USA.
Le Ann C MichaelsOregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.
Kelsey BrancaOregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.
Katrina RamseySchool of Public Health, Oregon Health & Science University, Portland, OR, USA.
Julie MitchellSchool of Public Health, Oregon Health & Science University, Portland, OR, USA.
Cynthia D MorrisSchool of Public Health, Oregon Health & Science University, Portland, OR, USA.
Lyle J FagnanOregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.
Rowena J DolorDuke Primary Care Research Consortium, Duke University, Durham, NC, USA.
Nancy ElderOregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.
David L HahnWisconsin Research & Education Network, University of Wisconsin-Madison, Madison, WI, USA.
Donald E NeaseState Networks of Colorado Ambulatory Partners & Practices, University of Colorado-Denver, Denver, CO, USA.
Jodi LapidusSchool of Public Health, Oregon Health & Science University, Portland, OR, USA.
Ricardo CibottiNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, Bethesda, MD, USA.
Julie BlockNational Eczema Association, San Rafael, CA, USA.
Eric L SimpsonDepartment of Dermatology, Oregon Health & Science University, Portland, OR, USA. simpsone@ohsu.edu.
Oregon Health & Science University · USDuke University · USResearch Network (United States) · USNational Eczema Association · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USUniversity of Colorado Denver · USUniversity of Wisconsin–Madison · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE TrialR01AR071057 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI SIMPSON, ERIC L · 2018 to 2023
$4.5M
NCATS NIH HHS UL1 TR002369NIAMS NIH HHS R01 AR071057NIAMS NIH HHS R01AR107517
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a common, chronic skin disorder often beginning in infancy. Skin barrier dysfunction early in life serves as a central event in the pathogenesis of AD. In infants at high risk of developing AD, preventative application of lipid-rich emollients may reduce the risk of developing AD. This study aims to measure the effectiveness of this intervention in a population not selected for risk via a pragmatic, randomized, physician-blinded trial in the primary care setting.

methodsInfant-parent dyads are recruited from a primary care practice participating through one of four practice-based research networks in Oregon, Colorado, Wisconsin, and North Carolina. Eligible dyads are randomized to the intervention (daily use of lipid-rich emollient) or the control (no emollient) group (n = 625 infants in each) and are followed for 24 months. The primary outcome is the cumulative incidence of physician-diagnosed AD and secondary outcomes include caregiver-reported measures of AD and development of other atopic diseases. Data collection occurs via chart review and surveys, with no study visits required. Data will be analyzed utilizing intention-to-treat principles. DISCUSSION: AD is a common skin condition in infants that affects quality of life and is associated with the development of other atopic diseases. If a safe intervention, such as application of lipid-rich emollients, in the general population effectively decreases AD prevalence, this could alter the guidance given by providers regarding routine skin care of infants. Because of the pragmatic design, we anticipate that this trial will yield generalizable results.

trial registrationClinicalTrials.gov: NCT03409367. Registered on 11 February 2018.

Indexed as

Administration, CutaneousCost-Benefit AnalysisDermatitis, AtopicEmollientsHumansIncidenceInfantMulticenter Studies as TopicPragmatic Clinical Trials as TopicPrimary PreventionQuality of LifeSkin CareSurveys and QuestionnairesTreatment OutcomeUnited StatesEmollientsAtopic dermatitisEczemaEmollientMoisturizerPractice-based research networkPragmatic

Identifiers

PMID32131885
PMCPMC7057622
OpenAlexW3010245775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.